Neuralink, Elon Musk’s brain-chip startup, has announced that it will begin recruiting for the first human trial of its brain implant designed for paralysis patients. The startup received approval from an independent review board for the trial, which aims to use a brain-computer interface (BCI) implant to enable paralyzed individuals to control a computer cursor or keyboard using their thoughts.
The trial will involve patients with paralysis due to cervical spinal cord injury or amyotrophic lateral sclerosis. However, the exact number of participants has not been disclosed, and the trial is expected to take about six years to complete.
Brain-Computer Interface Implant
The study will use a robot to surgically place the BCI implant in a region of the brain that controls the intention to move. Neuralink had initially hoped to implant its device in 10 patients but negotiated a lower number with the US Food and Drug Administration (FDA) due to safety concerns raised by the agency.
Ambitious Goals for Brain-Chip Technology
Elon Musk has ambitious goals for Neuralink’s brain-chip technology, envisioning its use in treating conditions like obesity, autism, depression, and schizophrenia. The startup had previously received FDA clearance for its first-in-human clinical trial but faced scrutiny for its handling of animal testing.
Long Road to Commercial Use Clearance
Even if the BCI device proves safe for human use, experts suggest that it could take more than a decade for Neuralink to secure commercial use clearance for the implant. The startup’s innovative technology holds promise for the treatment of various neurological conditions, but regulatory approval and safety evaluations remain essential steps in its development.
Neuralink’s approval for a human trial of its brain implant represents a significant milestone in the company’s efforts to develop brain-computer interface technology. While the trial’s primary focus is on assisting paralysis patients, Neuralink has broader aspirations for its technology in treating various neurological conditions. However, the path to commercial use clearance is expected to be lengthy and complex, involving rigorous safety evaluations and regulatory approvals